ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® º¸°í¼­ : ±¸¼º¿ä¼Òº°, À¯Çüº°, »çÁöº°, ¿ëµµº°, À̵¿¼ºº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Medical Exoskeleton Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Component, Type, Extremity, Application, Mobility, End Users, and Geography
»óǰÄÚµå : 1498577
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 240 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,285,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 9,110,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 11,935,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº 2023³â 3¾ï 7,491¸¸ ´Þ·¯¿¡¼­ 2031³â 32¾ï 674¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀº 2023³âºÎÅÍ 2031³â±îÁö ¿¬Æò±Õ 30.8%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºêÀÇ Áõ°¡¿Í ³úÁ¹Áß ¹× ±Ù°ñ°Ý°è ÁúȯÀÇ Áõ°¡¿Í °°Àº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ³ôÀº Á¦Ç° ºñ¿ë°ú ±ÔÁ¦ ¹®Á¦°¡ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½Åü Ȱµ¿ÀÇ °¨¼Ò¿Í ¾É¾Æ¼­ Çϴ Ȱµ¿ÀÇ ¿ìÀ§´Â SCI ȯÀÚÀÇ ½ÅüÀû, ½É¸®Àû »óŸ¦ ½É°¢ÇÏ°Ô ¾ÇÈ­½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ SCI¿Í °ü·ÃµÈ ÀÌÂ÷Àû ÇÕº´ÁõÀº »ý¸í ¿¹Èĸ¦ ´ÜÃà½Ãų ¼ö ÀÖ½À´Ï´Ù. ±¹¸³ÀÇÇеµ¼­°ü¿¡ µû¸£¸é ¸Å³â Àü ¼¼°èÀûÀ¸·Î 25¸¸-50¸¸ ¸í¿¡ °¡±î¿î ȯÀÚ°¡ SCI¸¦ ¾Î°í ÀÖ½À´Ï´Ù. µû¶ó¼­ SCI À¯º´·üÀÇ Áõ°¡¿Í SCI ȯÀÚ¸¦ À§ÇÑ ¿Ü°ñ°Ý »ç¿ë¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±âÀÇ ½ÃÀå ±âȸ

½Åü Ȱµ¿ÀÇ °¨¼Ò¿Í ÁÂ½Ä È°µ¿ÀÌ ¿ì¼¼ÇÑ °æ¿ì SCI ȯÀÚÀÇ ½ÅüÀû, ½É¸®Àû ¾ÇÈ­°¡ ½ÉÇØÁú ¼ö ÀÖÀ¸¸ç, SCI¿Í °ü·ÃµÈ ÀÌÂ÷Àû ÇÕº´ÁõÀº »ý¸í ¿¹Èĸ¦ ´ÜÃà½Ãų ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³ÀÇÇеµ¼­°ü¿¡ µû¸£¸é, ¸Å³â Àü ¼¼°èÀûÀ¸·Î 25¸¸-50¸¸ ¸í¿¡ °¡±î¿î ȯÀÚ°¡ SCI¸¦ ¾Î°í ÀÖ½À´Ï´Ù. ¿µ±¹ ô¼ö ¼Õ»ó ¿¬±¸, ÀçȰ ¹× »çȸ º¹±Í Çùȸ(Aspire, ¿µ±¹)°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é, ¿µ±¹¿¡¼­´Â ¸Å³â 2,500¸íÀÌ Ã´¼ö ¼Õ»ó Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ô¼ö¼Õ»ó Åë°è¼¾ÅÍ(National Spinal Cord Injury Statistical Center)ÀÇ Ã߻꿡 µû¸£¸é, ¹Ì±¹¿¡¼­´Â ¾à 32¸¸ ¸íÀÌ ¿Ü»ó¼º ô¼ö¼Õ»óÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿øÀÇ º¸°í¿¡ µû¸£¸é, ÀÌ·¯ÇÑ »ç·ÊÀÇ Áõ°¡´Â Àü ¼¼°èÀûÀ¸·Î °¡Àå Àαâ ÀÖ´Â ½ºÆ÷Ã÷ Ȱµ¿À¸·Î ºÎ»óÇÑ ¸ðÅÍÅ©·Î½º¿Í ¿ÀÅä¹ÙÀÌ °æÁÖ¿¡ ±âÀÎÇϸç, ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î ¸Å³â ¾à 1,190¸¸ ¸íÀÌ ±³Åë»ç°í·Î »ç¸ÁÇϰí 2,000¸¸-5,000¸¸ ¸íÀÌ »ç¸Á¿¡ À̸£Áö ¾Ê´Â ºÎ»óÀ» ÀÔÀ¸¸ç, ±× Áß »ó´ç¼ö°¡ Àå¾Ö¸¦ ÀÔ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ¸ÞÀÌ¿ä Ŭ¸®´ÐÀÇ Ã߻꿡 µû¸£¸é, ´ÙÀ̺ù, ³ó±¸, Ã౸ µî ½ºÆ÷Ã÷¿Í ¿îµ¿À¸·Î ÀÎÇÑ Ã´¼ö ¼Õ»óÀÌ ÀüüÀÇ 10%¿¡ ´ÞÇÑ´Ù°í ÇÕ´Ï´Ù. ¶óÀÌÇÁ¿öµå¿Í °°Àº ±â¾÷µéÀº ô¼ö ¼Õ»ó ȯÀÚ°¡ ÅëÁõ ¾øÀÌ ½Åü Ȱµ¿À» ÇÒ ¼ö ÀÖ´Â ¿Ü°ñ°Ý °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, SCI Àα¸ÀÇ ¾à 20%´Â ÇöÀç ReWalk Personal Exoskeleton ¶Ç´Â ReWalk Rehabilitation ExoskeletonÀÇ ÀÓ»ó½ÃÇè Èĺ¸ÀÚ·Î °£ÁÖµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á¿ë ¿Ü°ñ°Ý ¼ÒÇÁÆ® ¿Ü°ñ°Ý ½´Æ® ÀåÄ¡´Â SCI ȯÀÚ¿¡°Ô »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ SCI À¯º´·ü Áõ°¡¿Í SCI ȯÀÚ¸¦ À§ÇÑ ¿Ü°ñ°Ý »ç¿ë¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎ

¿Ü°ñ°Ý ½Ã½ºÅÛÀº ÀÇ·á ¾÷°è¿¡¼­ ÀçȰ ¹× Ä¡·á ¼­ºñ½º¸¦ ¹Þ´Â ȯÀÚ¸¦ Áö¿øÇÏ´Â Âø¿ëÇü ·Îº¿À¸·Î ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ¿Ü°ñ°Ý Á¦Á¶¾÷üµéÀº ´õ ¸¹Àº ¸ñÀû°ú ½Å·Ú¼ºÀ» Á¦°øÇϱâ À§ÇØ Á¦Ç° °³¼±¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ³ôÀº Á¦Ç° ºñ¿ë°ú ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ºÎÁ· µî ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Àüµ¿½Ä ÇϺΠ¿Ü°ñ°ÝÀº ¼­ºñ½º ¹× À¯Áöº¸¼ö¸¦ Á¦¿ÜÇÏ°í ¹Ì±¹¿¡¼­ 70,000-120,000´Þ·¯¿¡ ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ¿Ü°ñ°ÝÀÇ ³ôÀº °¡°ÝÀÌ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, »ê¾÷°è¿Í ±ÔÁ¦ »çÀÌ¿¡´Â Å« °ÝÂ÷°¡ Á¸ÀçÇϸç, ReWalk Robotics, Ekso Bionics Holding, Parker Hannifin Corporation, Cyberdyne Inc., Hocomo AG µîÀÌ FDAÀÇ ½ÂÀÎÀ» ¹ÞÀº ¸î ¾È µÇ´Â ±â¾÷µéÀÔ´Ï´Ù. ÀçȰ ¹× ±âŸ ÀÓ»ó Àû¿ë¿¡ ÀÖ¾î ´Ù¾çÇÑ Áß¿äÇÑ ¿ëµµ¸¦ °¡Áö°í ÀÖ¾î ¾ö°ÝÇÑ ±ÔÁ¦¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿Ü°ñ°ÝÀÇ À§Çè °ü¸® ¹× ¹ý·üµµ ÃæºÐÈ÷ ´Ù·ç¾îÁöÁö ¾Ê¾Ò½À´Ï´Ù. µû¶ó¼­ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Á¦Ç°ÀÇ ³ôÀº ºñ¿ë°ú ±ÔÁ¦ ¹®Á¦·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ±¸¼º¿ä¼Ò¿¡ µû¶ó Çϵå¿þ¾î¿Í ¼ÒÇÁÆ®¿þ¾î·Î ³ª´¹´Ï´Ù. Çϵå¿þ¾îÀÇ ÇÏÀ§ ºÎ¹®Àº ¼¾¼­, ¾×Ãß¿¡ÀÌÅÍ, Àü¿ø °ø±Þ ÀåÄ¡, Á¦¾î ½Ã½ºÅÛ ¹× ±âŸ·Î ³ª´¹´Ï´Ù. ¾×Ãß¿¡ÀÌÅÍ´Â °ø¾Ð ¾×Ãß¿¡ÀÌÅÍ, À¯¾Ð ¾×Ãß¿¡ÀÌÅÍ, Àü±â ¾×Ãß¿¡ÀÌÅÍ, ±â°è½Ä ¾×Ãß¿¡ÀÌÅÍ, Çü»ó ±â¾ï ÇÕ±Ý ¾×Ãß¿¡ÀÌÅÍ ¹× ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù.

À¯Çüº°·Î ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº µ¿·Â½Ä ¿Ü°ñ°Ý°ú ¼öµ¿½Ä ¿Ü°ñ°ÝÀ¸·Î ±¸ºÐµÇ¸ç, 2023³â ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ µ¿·Â½Ä ¿Ü°ñ°Ý ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

»çÁö¸¦ ±âÁØÀ¸·Î ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ÇÏü ¿Ü°ñ°Ý, »óü ¿Ü°ñ°Ý, Àü½Å ¿Ü°ñ°ÝÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù. ÇÏü ¿Ü°ñ°Ý ºÎ¹®ÀÌ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¿ëµµ¿¡ µû¶ó ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ô¼ö ¼Õ»ó, ´Ù¹ß¼º °æÈ­Áõ, ³úÁ¹Áß, ³ú¼º¸¶ºñ, ÆÄŲ½¼º´, ±âŸ·Î ³ª´¹´Ï´Ù. ô¼ö ¼Õ»ó ºÐ¾ß°¡ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

À̵¿¼ºÀ» ±âÁØÀ¸·Î ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº À̵¿½Ä ¿Ü°ñ°Ý°ú °íÁ¤½Ä ¿Ü°ñ°ÝÀ¸·Î ³ª´¹´Ï´Ù. ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ À̵¿½Ä ¿Ü°ñ°Ý ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó ÀçȰ¼¾ÅÍ, ¹°¸®Ä¡·á¼¾ÅÍ, Àå±â¿ä¾ç¼¾ÅÍ, ȨÄɾî ȯ°æ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ÀçȰ¼¾ÅÍ ºÐ¾ß°¡ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

Ç÷¾×°¡½º ¹× ÀüÇØÁú ºÐ¼®±â ½ÃÀå Áö¿ªº° °³¿ä

½ÃÀå ±â¾÷µéÀº ¿Ü°ñ°Ý »ç¾÷À» °­È­Çϱâ À§ÇØ ¹Ì±¹¿¡¼­ Á¦Ç° Çã°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù Ekso Bionics Holdings Inc.´Â ¹Ì±¹ ½ÄǰÀǾ౹À¸·ÎºÎÅÍ ´Ù¹ß¼º °æÈ­Áõ ȯÀÚ¸¦ À§ÇÑ EksoNR ·Îº¿ ¿Ü°ñ°ÝÀÇ ÆÇ¸Å ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌó·³ ¹Ì±¹ ÇコÄÉ¾î ¾÷°èÀÇ ´Ù¾çÇÑ ÀÇ·á±â±â ´ë±â¾÷µéÀÇ ½ÅÈï ½ÃÀå °³Ã´Àº ÇâÈÄ ¸î ³â µ¿¾È ¹Ì±¹ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀ» ´õ¿í Ȱ¼ºÈ­½Ãų °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

FDA´Â Á¦Ç°ÀÌ ÀüÀڱ⠱â¼ú°ú ȣȯµÇ°í, À¯È¿ÇÑ ¼ÒÇÁÆ®¿þ¾î, Àç·á ±¸¼º ¹× ¸ð¾çÀ» °¡Áö°í ÀÖÀ¸¸ç, ÀϺΠºñÀÓ»ó ¼º´É Å×½ºÆ®, ÀÓ»ó½ÃÇè, ÀÓ»ó½ÃÇè ¹× ±³À° ÇÁ·Î±×·¥¿¡ ÀûÇÕÇϰí ÇÊ¿äÇÑ ¼¼ºÎ »çÇ×ÀÌ Ç¥½ÃµÇ¾î ÀÖ´Â °æ¿ì¿¡¸¸ ¹Ì±¹ Àü¿ª¿¡¼­ ¿Ü°ñ°Ý Á¦Ç°À» ÆÇ¸ÅÇÒ ¼ö ÀÖµµ·Ï Çã¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ±¹³»¿¡¼­ ±ÔÁ¦°¡ ¾ö°ÝÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀº ôÃß ¼Õ»ó, ±Ù°ñ°Ý°è Àå¾Ö ¹× ±âŸ °ü·Ã °Ç°­ »óÅÂÀÇ Áõ°¡·Î ÀÎÇØ ÃËÁøµÉ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹Ì±¹ ½Å°æ¿Ü°ú ÇÐȸ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â ¾à 17,000°ÇÀÇ »õ·Î¿î ô¼ö ¼Õ»ó(SCI)ÀÌ ¹ß»ýÇÕ´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ ´Ù¹ß¼º °æÈ­Áõ Çùȸ¿¡ µû¸£¸é 2020³â¿¡´Â ¹Ì±¹¿¡¼­ ¾à 100¸¸ ¸íÀÌ ´Ù¹ß¼º °æÈ­ÁõÀ» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. µû¶ó¼­ ÀÇ·á¿ë ¿Ü°ñ°Ý¿¡ ´ëÇÑ ¼ö¿ä´Â ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå »óȲ

Á¦5Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

Á¦7Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ÄÄÆ÷³ÍÆ®º°

Á¦8Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦9Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : »çÁöº°

Á¦10Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦11Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ¸ðºô¸®Æ¼º°

Á¦12Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦13Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : Áö¿ªº° ºÐ¼®

Á¦14Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ¾÷°è »óȲ

Á¦15Àå ±â¾÷ °³¿ä

Á¦16Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global medical exoskeleton market is expected to reach US$ 3,206.74 million in 2031 from US$ 374.91 million in 2023. The market is estimated to grow with a CAGR of 30.8% from 2023 to 2031.

Key factors driving the market such as rising number of strategic initiatives and growing incidences of strokes and musculoskeletal disorder are expected to propel the growth of the market. However, high cost of the products and regulatory concern is the major factor hindering the market growth. Reduced physical activity and the predominance of seated activities can lead to severe physical and psychological deterioration in people suffering from SCI. Secondary complications related to SCI can also reduce life expectancies. According to the National Library of Medicine, nearly 250,000-500,000 patients suffer from SCIs every year worldwide. Thus, the increase in the prevalence of SCI and ongoing research for the use of exoskeletons for SCI patients can be expected to fuel the market growth during the forecast period.

Market Opportunities of Blood Gas And Electrolyte Analyzer Market-

Reduced physical activity and the predominance of seated activities can lead to severe physical and psychological deterioration in people suffering from SCI. Secondary complications related to SCI can also reduce life expectancies. According to the National Library of Medicine, nearly 250,000-500,000 patients suffer from SCIs every year worldwide. According to a report published by the Association for Spinal Injury Research, Rehabilitation and Reintegration (Aspire, UK), ~2,500 people are diagnosed with SCIs annually in the UK. Currently, ~50,000 people are living with these injuries in the UK. The National Spinal Cord Injury Statistical Center estimates that ~320,000 people are living with traumatic SCIs in the US. An elevated number of cases is attributed to motocross and motorcycling competitions emerging as the most popular sporting activities worldwide, as per the National Institute of Health report. According to the WHO, globally, ~1.19 million people die every year in road crashes, and 20-50 million people suffer non-fatal injuries, with many incurring disabilities. Similarly, according to the Mayo Clinic estimates, sports and athletic activities such as diving in shallow water, basketball, and football cause ~10% of spinal cord injuries. Companies such as Lifeward are focusing on developing exoskeletons that help patients with SCI perform physical activities without pain. For instance, about 20% of the SCI population can be considered candidates for clinical trials of the current ReWalk Personal Exoskeleton or ReWalk Rehabilitation Exoskeleton. Moreover, soft exo-suit devices in medical exoskeletons can be used for patients suffering from SCI. Thus, the increase in the prevalence of SCI and ongoing research for the use of exoskeletons for SCI patients can be expected to fuel the market growth during the forecast period.

Factor Hampering Blood Gas and Electrolyte Analyzer Market

Exoskeleton systems are accepted in the medical industry as wearable robots that support patients who receive rehabilitation and therapeutic services. Manufacturers of exoskeletons focus on improving products to offer more purpose and reliability. However, the market faces several challenges, such as the high cost of the product and fewer approvals from the regulatory bodies. For instance, the powered lower exoskeleton is available between US$ 70,000 and US$ 120,000, excluding the services and maintenance. Therefore, the high price of the exoskeleton is hampering the market growth.

Further, the regulatory gap between industry and regulation is vast. ReWalk Robotics, Ekso Bionics Holding, Parker Hannifin Corporation, Cyberdyne Inc., and Hocomo AG are among a few companies to have received approval from the FDA. As exoskeletons are used as therapeutic devices and have various important applications in rehabilitation and other clinical applications, it has stringent regulations. Additionally, the risk management and laws for exoskeletons have not been addressed adequately. Thus, owing to the factors mentioned above, the high cost of the product and regulatory concerns are impeding the market growth

Based on component, the medical exoskeleton market is bifurcated inti hardware and software. The hardware subsegment is divided into sensors, actuators, power sources, control systems, and others. Actuators are further segmented into pneumatic actuators, hydraulic actuators, electric actuators, mechanical actuators, shape memory alloy actuators, and others

Based on type, the medical exoskeleton market is segmented into powered exoskeleton and passive exoskeleton. The powered exoskeleton segment held the largest share in the medical exoskeleton market in 2023.

Based on extremity, the medical exoskeleton market is segmented into lower body exoskeleton, upper body exoskeleton, full body exoskeleton. The lower body exoskeleton segment held the largest share in the medical exoskeleton market.

Based on application, the medical exoskeleton market is segmented into spinal cord injury, multiple sclerosis, stroke, cerebral palsy, Parkinson's disease, and others. The spinal cord injury segment held the largest share in the medical exoskeleton market.

Based on mobility, the medical exoskeleton market is bifurcated into mobile exoskeleton and stationary exoskeleton. The mobile exoskeleton segment held the largest share in the medical exoskeleton market.

Based on end user, the medical exoskeleton market is segmented into rehabilitation centers, physiotherapy centers, long term care centers, homecare settings, and others. The rehabilitation centers segment held the largest share in the medical exoskeleton market.

Blood Gas and Electrolyte Analyzer Market: Regional Overview

Market players are receiving product approvals in the US to enhance the exoskeleton business. For instance, in July 2022, Ekso Bionics Holdings Inc. received marketing approval from the US Food and Drug Administration for its EksoNR robotic exoskeleton to use in patients with multiple sclerosis. Thus, the growing developments by various medical device giants in the US healthcare industry will further boost the market for medical exoskeletons in the country in the upcoming years.

The FDA clears the exoskeleton products for marketing across the US only when the products are compatible with electromagnetics technology; have valid software, material composition, and geometry; suitable for several nonclinical performance testings, clinical testings, training programs; and are labeled with essential details. Thus, the market for medical exoskeletons is highly regulated in the country. The growth of the market is estimated to propel due to the rising number of spinal injuries, musculoskeletal disorders, and other related health conditions. According to the American Association of Neurological Surgeons, nearly 17,000 new spinal cord injuries (SCIs) occur in the US every year. Further, according to the National Multiple Sclerosis Society, about 1 million people in 2020 were affected by multiple sclerosis in the US. Thus, the demand for medical exoskeletons is likely to grow during the forecast period

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Medical Exoskeleton Market Landscape

5. Medical Exoskeleton Market - Key Market Dynamics

6. Medical Exoskeleton Market - Global Market Analysis

7. Medical Exoskeleton Market Analysis - by Component

8. Medical Exoskeleton Market Analysis - by Type

9. Medical Exoskeleton Market Analysis - by Extremity

10. Medical Exoskeleton Market Analysis - by Application

11. Medical Exoskeleton Market Analysis - by Mobility

12. Medical Exoskeleton Market Analysis - by End Users

13. Medical Exoskeleton Market - Geographical Analysis

14. Medical Exoskeleton Market - Industry Landscape

15. Company Profiles

16. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â